Abstract: Objective: To explore the expression of Survivin mRNA and XIAP mRNA in ovarian tissues and LPA and serum CA125 in plasma of patients with epithelial ovarian carcinoma and evaluate their correlation with the clinicopathological and other molecular parameters. Methods: The expression of Survivin mRNA and XIAP mRNA was determined by RT-PCR in 50 epithelial ovarian carcinoma tissues and 12 normal ovarian tissues， and the level of plasma LPA was determined by a reagent in 50 patients with epithelial ovarian carcinoma, 44 with ovarian benign diseases and 20 healthy women． Results: Expression of Survivin mRNA and XIAP mRNA had significant differences between epithelial ovarian carcinoma and normal ovarian tissues (P<0.05). Expression of Survivin mRNA and XIAP mRNA increased in the 50 epithelial ovarian carcinoma tissues, which were related to the clinicopathological stage, degree, and lymph node metastasis (P<0.05). Expression of survivin mRNA correlated with that of XIAP mRNA in 50 epithelial ovarian carcinoma tissues rs=0.03(P＜0.05). In the group of ovarian carcinoma, the mean LPA in plasma was(7.67±3.02)μmol/L and the positive rate was 78.0%, while in the group of ovarian benign diseases, they were(2.734±1.471)μmol/L and 27.3%, respectively，　in the group of healthy women, they were(1.557±1.294)μmol/L and 5%, respectively. The LPA specificity was 75.0%，which was higher than CA125-s. The sensitivity of LPA was 71.4%，which was higher than that of CA125 (28.6%)（P<0.05）. The level of LPA in stageⅡ-Ⅳ was significantly higher than that in stageⅠ (P<0.05). There were no statistical significance among stagesⅡ-Ⅳ（P>0.05）, and no significant relations between the LPA value and the pathologic types（P>0.05）. Conclusions: Survivin and XIAP are candidate tumor genes related to the development of ovarian carcinoma. In early diagnosis of ovarian carcinoma, the specificity and sensitivity of LPA are both higher than those of CA125.

Key words: Ovarian neoplasms, Genes, X-linked inhibitor of apoptosis protein, Genes, Survivin, Reverse Transcriptase-Polymerase Chain Reaction, Lysophosphatidic acid